BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 2151405)

  • 1. [GnRH-analogs in the therapy of uterine myomatosis].
    Wieacker P; Geisthövel F; Adelberger V; Breckwoldt M
    Ther Umsch; 1990 Dec; 47(12):951-7. PubMed ID: 2151405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gonadotropin-releasing hormone (GnRH) action on uterine leiomyomata is not mediated by uterine GnRH receptors.
    Neuman M; Langer R; Golan A; Bukovsky I; Caspi E; Koch Y
    Fertil Steril; 1991 Aug; 56(2):364-6. PubMed ID: 1649060
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term follow-up of patients with uterine fibroids after treatment with the LHRH agonist buserelin.
    Matta WH; Shaw RW; Nye M
    Br J Obstet Gynaecol; 1989 Feb; 96(2):200-6. PubMed ID: 2495020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids.
    Lethaby A; Vollenhoven B; Sowter M
    Cochrane Database Syst Rev; 2000; (2):CD000547. PubMed ID: 10796723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids.
    Lethaby A; Vollenhoven B; Sowter M
    Cochrane Database Syst Rev; 2001; (2):CD000547. PubMed ID: 11405968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of uterine fibroids with agonist analogs of gonadotropin-releasing hormone.
    Kessel B; Liu J; Mortola J; Berga S; Yen SS
    Fertil Steril; 1988 Mar; 49(3):538-41. PubMed ID: 3277869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial.
    Carr BR; Marshburn PB; Weatherall PT; Bradshaw KD; Breslau NA; Byrd W; Roark M; Steinkampf MP
    J Clin Endocrinol Metab; 1993 May; 76(5):1217-23. PubMed ID: 8496313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-surgical treatment of uterine myomas with LH-RH agonists.
    D'Addato F; Repinto A; Andreoli C
    Clin Exp Obstet Gynecol; 1992; 19(1):45-50. PubMed ID: 1535032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toward removing uterine fibroids without surgery: subcutaneous infusion of a luteinizing hormone-releasing hormone agonist commencing in the luteal phase.
    Healy DL; Lawson SR; Abbott M; Baird DT; Fraser HM
    J Clin Endocrinol Metab; 1986 Sep; 63(3):619-25. PubMed ID: 3090092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormonal therapy before surgical treatment for uterine leiomyomas.
    Moghissi KS
    Surg Gynecol Obstet; 1991 Jun; 172(6):497-502. PubMed ID: 1827931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uterine leiomyomata and sterility: therapy with gonadotropin-releasing hormone agonists and leiomyomectomy.
    Kuhlmann M; Gärtner A; Schindler EM; Regidor PA; Bühler K; Schindler AE
    Gynecol Endocrinol; 1997 Jun; 11(3):169-74. PubMed ID: 9209897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of uterine fibroids with implants of gonadotropin-releasing hormone agonist: assessment by hysterography.
    Donnez J; Schrurs B; Gillerot S; Sandow J; Clerckx F
    Fertil Steril; 1989 Jun; 51(6):947-50. PubMed ID: 2498131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triptorelin to prevent hysterectomy in patients with leiomyomas.
    van Leusden HA
    Lancet; 1988 Aug; 2(8609):508. PubMed ID: 2900426
    [No Abstract]   [Full Text] [Related]  

  • 14. A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin "add-back" regimens for women with leiomyomata uteri.
    Friedman AJ; Daly M; Juneau-Norcross M; Rein MS; Fine C; Gleason R; Leboff M
    J Clin Endocrinol Metab; 1993 Jun; 76(6):1439-45. PubMed ID: 8501148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of uterine fibroid with triptorelin before hysterectomy.
    Loong EP; Lo KW
    Chin Med J (Engl); 1998 Jan; 111(1):67-70. PubMed ID: 10322658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of a gonadotropin-releasing hormone agonist in the treatment of uterine leiomyomata: long-term follow-up.
    Letterie GS; Coddington CC; Winkel CA; Shawker TH; Loriaux DL; Collins RL
    Fertil Steril; 1989 Jun; 51(6):951-6. PubMed ID: 2498132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gonadotropin-releasing hormone specific binding sites in uterine leiomyomata.
    Wiznitzer A; Marbach M; Hazum E; Insler V; Sharoni Y; Levy J
    Biochem Biophys Res Commun; 1988 May; 152(3):1326-31. PubMed ID: 2837183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous injection or infusion of gonadotropin releasing-hormone agonist buserelin in the treatment of enlarged uteri harboring leiomyomata.
    Franssen AM; Willemsen WN; Corbey RS; Doesburg WH; van 't Veen AJ; Rolland R
    Eur J Obstet Gynecol Reprod Biol; 1991 Jul; 40(3):221-8. PubMed ID: 1908799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of leiomyomata with intranasal or subcutaneous leuprolide, a gonadotropin-releasing hormone agonist.
    Friedman AJ; Barbieri RL; Benacerraf BR; Schiff I
    Fertil Steril; 1987 Oct; 48(4):560-4. PubMed ID: 3115833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of LHRH analogue action in uterine fibroids.
    Shaw RW
    Horm Res; 1989; 32 Suppl 1():150-3. PubMed ID: 2533145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.